The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Immune cell calender 25
Sherlock-MS-Blog
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English (UK)
Deutsch
English (UK)
Chances and Challenges of Registry-Based Pharmacovigilance in Multiple Sclerosis: Lessons Learnt from the Implementation of the Multicenter REGIMS Registry
MASC
Jahr
Publikationsjahr
2021
Autoren
Autorenliste der Publikation
Simbrich A, Thibaut J, Khil L, Maximov S, Wiendl H, Berger K; REGIMS Investigators.
Verlag
Publisher-Information
Drug Saf. 2021 Jan;44(1):7-15.
Link
Zur Publikation (externer Server)
https://doi.org/10.1007/s40264-020-01007-1
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Management & Science
MASC
2021
Variations in neuronal cytoskeletal integrity affect directed communication in distributed networks during inhibitory control
Multiple Sclerosis
Jahr
2025
Patient Perspectives on Healthcare Utilization During the COVID-19 Pandemic in People with Multiple Sclerosis—A Longitudinal Analysis
Multiple Sclerosis
Jahr
2025
Editorial: Digital twins in medicine—transition from theoretical concept to tool used in everyday care
MASC
Jahr
2025
Digital Representation of Patients as Medical Digital Twins: Data-Centric Viewpoint
MASC
Jahr
2025
Cost–consequence analysis of early vs. delayed natalizumab use in highly active relapsing–remitting multiple sclerosis: a simulation study
MASC
Jahr
2025